Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Search
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Living Independence
Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Heidelberg Transforming Science Day 2025 - Save the Date
The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Skin Diseases
Skin Diseases
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Future Leaders in Veterinary Medicine and Research
Through the Boehringer Ingelheim Veterinary Scholars Program, we offer opportunities for students to gain research experience and explore new career paths.
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Cities join forces for stroke care improvements
Learn how Angels Cities unite to swiftly address stroke symptoms. Quick collaboration saves crucial minutes, minimizing stroke’s devastating effects.
Sustainable Development - Our Commitment
Our Commitment
Collaboration in Oncology
Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.
Access to Healthcare Strategy Sustainable Access Models
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Partnering Culture
Partnering Culture
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.